Physician profile
Anna Seay
NPI 1821435207
$2,411.43
in general payments reported to CMS, 2019-2025
26 companies · $586 in 2025
The $586 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $743 · 2020: $125 · 2021: $187 · 2023: $349 · 2024: $422 · 2025: $586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,356.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $578.14 | 2021-2025 | |
| Novo Nordisk INC | $527.13 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $209.78 | 2019-2023 | Arexvy, Trelegy Ellipta, Shingrix |
| Janssen Pharmaceuticals, INC | $157.34 | 2019-2023 | Xarelto |
| Lilly USA, LLC | $154.49 | 2019-2025 | Mounjaro, Zepbound |
| Abbott Laboratories | $129.37 | 2023 | Mitraclip |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $77.24 | 2019-2024 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $68.84 | 2019 | |
| Amgen INC. | $57.36 | 2019 | |
| Phathom Pharmaceuticals, INC. | $56.07 | 2024-2025 | Voquezna |
| Pfizer INC. | $42.13 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $39.05 | 2019 | |
| Viatris Specialty LLC | $31.36 | 2025 | Yupelri |
| Amarin Pharma, INC. | $31.15 | 2019 | |
| Mylan Specialty L.P. | $30.86 | 2019-2024 | Yupelri |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $29.06 | 2019 | |
| Octapharma USA, INC. | $28.00 | 2025 | Fibryga |
| Dexcom, INC. | $27.57 | 2024 | Dexcom G6 Transmitter |
| Daiichi Sankyo INC. | $27.06 | 2025 | Injectafer |
| Exact Sciences Corporation | $24.36 | 2024 | Cologuard Collection Kit |
| Insulet Corporation | $19.35 | 2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $18.21 | 2023 | Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $12.71 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.85 | 2019 | |
| Allergan, INC. | $11.77 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Seay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.